by jtcir-auto | Feb 15, 2024 | Press Releases
Aeterna Zentaris Board recommends shareholders vote FOR all resolutions, to create a diversified biopharmaceutical company with a compelling value propositionMore information and materials available at www.AEZSmerger.comShareholders with questions or who require...
by jtcir-auto | Jan 10, 2024 | Uncategorized
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
by jtcir-auto | Dec 14, 2023 | Press Releases
TORONTO and EDMONTON, Dec. 14, 2023 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna”) and Ceapro Inc. (TSXV: CZO) (OTCQX: CRPOF) (“Ceapro”), two innovative biopharmaceutical development companies, today...
by jtcir-auto | Dec 14, 2023 | Press Releases
TORONTO and EDMONTON, Dec. 14, 2023 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna”) and Ceapro Inc. (TSXV: CZO) (OTCQX: CRPOF) (“Ceapro”), two innovative biopharmaceutical development companies, today...
by jtcir-auto | Nov 9, 2023 | Press Releases
– Launch of Ghryvelin™ in a number of key countries in the European Economic Area – Approval of Macrilen® in South Korea in September – Ended the quarter with $38.8 million in cash, expected to fund operations and advancement of priority...